Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
Two acquisitions of cell therapy companies could take them in almost opposite directions.
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
A $4.9bn buyout of Forty Seven means that Gilead remains focused on oncology, though cell therapy bulls are none the wiser.
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.
For diabetes devices interoperability is key, and partnerships between Insulet, Dexcom and Abbott show that rival groups see the benefits of working together.
Investors in Conatus, and especially those in Newlink, should question how valuations of the groups' reversing acquirers have been calculated.
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.